Renee Ryan
Known title: DirectorCIK: 0001855576
Associated companies
Transaction History
| NPCE | ▲ Buy | Grant | 2,890 | $0 | 6/5/2026 | View on chart |
| NPCE | ▲ Buy | Grant | 2,890 | $0 | 6/5/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating
Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating. Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.